Bio-Rad Laboratoriesvs.Labcorp
BIO vs LH · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Labcorp is about 2.7× larger than Bio-Rad Laboratories by market cap; Labcorp trades at the lower P/E (26.1 vs 43.5); year to date, Labcorp leads (+35.3% vs +26.0%).
Supply-chain link: Bio-Rad Laboratories supplies Labcorp.
Side by side
| BIO | LH | |
|---|---|---|
| Market cap | $9.7B | $26.2B |
| Price | $390.34 | $337.68 |
| Today | +2.2% | −0.5% |
| Return YTD | +26.0% | +35.3% |
| Return 1Y | +25.7% | +22.0% |
| P/E | 43.5 | 26.1 |
| P/S | 3.7 | 1.8 |
| P/B | 1.3 | 3.0 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →LabcorpLH
Samples from across the US end up in Labcorp's laboratories, which handle routine clinical testing alongside genomics and specialty assays. A contract research arm works for drug developers.
Full LH profile →More BIO & LH comparisons
Other head-to-heads in the Diagnostics segment.